Claravis is an anti-acne medication used to treat the most severe form of acne (nodular) that cannot be cleared up by any other acne treatments, including antibiotics. Claravis, much like accutane, should only be used under the most strict circumstances as it can cause severe side effects.
Claravis should not be taken by women that are pregnant, are planning on becoming pregnant, or that become pregnant during treatment with Claravis. You also should not take Claravis if you are breastfeeding. Claravis should also not be taken by people that are allergic to anything in it.
The side effects of Claravis include birth defects (deformed babies), miscarriage, death of a baby, premature birth, increased pressure on the brain, stomach problems, bone and muscle problems, and hearing and vision problems. This list is by no means complete. The less serious side effects include dry skin, chapped lips, dry eyes, and dry nose which may lead to nosebleed.
In order to gain access to Claravis and other drugs like it, patients must take part in the iPledge program. This is a program that started in 2005. Every person on Claravis must be a registered as a patient. Females that are prescribed Claravis must use 2 forms of contraception that are registered with the iPledge program. Also, female patients must have negative results on 2 pregnancy tests before they can fill their prescription as well as take a pregnancy test before each refill of the prescription. In addition to patients having to be registered with iPledge, doctors and pharmacies must be registered as well to prescribe and fill Claravis prescriptions. This is all an effort to reduce the chances of serious birth defects.
In addition to the birth defect problem with Claravis, there is also a warning concerning the increase of suicidal thoughts or actions while on Claravis. Everyone on Claravis should be observed for signs of depression and suicide.
The FDA is keeping track of the reports of birth defects and suicidal thoughts and is trying to keep people appraised of any new developments.